Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy

Future Oncology Ahead of Print.


from Cancer via ola Kala on Inoreader http://ift.tt/1VffGhi
via IFTTT